These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 3208800)
1. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Howell A; Mackintosh J; Jones M; Redford J; Wagstaff J; Sellwood RA Eur J Cancer Clin Oncol; 1988 Oct; 24(10):1567-72. PubMed ID: 3208800 [TBL] [Abstract][Full Text] [Related]
2. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Thewes B; Meiser B; Duric VM; Stockler MR; Taylor A; Stuart-Harris R; Links M; Wilcken N; McLachlan SA; Phillips KA; Beith J; Boyle F; Friedlander ML Lancet Oncol; 2005 Aug; 6(8):581-8. PubMed ID: 16054569 [TBL] [Abstract][Full Text] [Related]
3. [A randomized trial of endocrine therapy, chemotherapy, and chemo-endocrine therapy in advanced breast cancer]. Tashiro H; Nomura Y; Hisamatsu K Gan To Kagaku Ryoho; 1990 Dec; 17(12):2369-73. PubMed ID: 2260873 [TBL] [Abstract][Full Text] [Related]
4. Results of endocrine therapy do not predict response to chemotherapy in advanced breast cancer. Steiner R; Stewart JF; Rubens RD Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1559-63. PubMed ID: 6685641 [TBL] [Abstract][Full Text] [Related]
5. [Progress in breast cancer chemo-endocrine therapy from the survival standpoint]. Nomura Y Gan To Kagaku Ryoho; 1995 May; 22(6):726-31. PubMed ID: 7755380 [TBL] [Abstract][Full Text] [Related]
6. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen. Mouridsen HT; Rose C; Engelsmann E; Sylvester R; Rotmensz N J Steroid Biochem; 1985 Dec; 23(6B):1141-6. PubMed ID: 3912619 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Swain SM; Sorace RA; Bagley CS; Danforth DN; Bader J; Wesley MN; Steinberg SM; Lippman ME Cancer Res; 1987 Jul; 47(14):3889-94. PubMed ID: 3036348 [TBL] [Abstract][Full Text] [Related]
8. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction. Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476 [TBL] [Abstract][Full Text] [Related]
9. [Combination chemo-endocrine therapy of metastatic and stage IV breast cancer with cyclophosphamide, adriamycin, prednisolone and tamoxifen (CAPT)--with special reference to management of brain and liver metastasis]. Nakamura Y; Kawaguchi M; Hata A; Watanabe H; Ueki Y; Oribe T; Koba F; Takamuku K Gan To Kagaku Ryoho; 1989 Feb; 16(2):243-50. PubMed ID: 2919892 [TBL] [Abstract][Full Text] [Related]
10. Complete remission following endocrine or combined cytotoxic and hormonal treatment in advanced breast cancer. A retrospective analysis. Pedrazzini A; Cavalli F; Brunner KW; Goldhirsch A; Mermillod B Oncology; 1987; 44(1):51-9. PubMed ID: 3550556 [TBL] [Abstract][Full Text] [Related]
11. [Chemo-endocrine therapy of advanced breast cancer]. Nomura Y Gan To Kagaku Ryoho; 1988 Dec; 15(12):3214-20. PubMed ID: 2973769 [TBL] [Abstract][Full Text] [Related]
12. Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer. Bianco AR; De Placido S; Perrone F; Carlomagno C; De Laurentiis M; Del Mastro L; Lauria R; Marinelli A; Gallo C Ann N Y Acad Sci; 1993 Nov; 698():330-8. PubMed ID: 8279772 [No Abstract] [Full Text] [Related]
13. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience. Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583 [TBL] [Abstract][Full Text] [Related]
14. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. Lippman ME; Sorace RA; Bagley CS; Danforth DW; Lichter A; Wesley MN NCI Monogr; 1986; (1):153-9. PubMed ID: 3022156 [TBL] [Abstract][Full Text] [Related]
15. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen. Mouridsen HT; Rose C; Engelsman E; Sylvester R; Rotmensz N Eur J Cancer Clin Oncol; 1985 Mar; 21(3):291-9. PubMed ID: 3891357 [TBL] [Abstract][Full Text] [Related]
16. A systematic overview of chemotherapy effects in breast cancer. Bergh J; Jönsson PE; Glimelius B; Nygren P; Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936 [TBL] [Abstract][Full Text] [Related]
17. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Bontenbal M; Foekens JA; Lamberts SW; de Jong FH; van Putten WL; Braun HJ; Burghouts JT; van der Linden GH; Klijn JG Br J Cancer; 1998; 77(1):115-22. PubMed ID: 9459155 [TBL] [Abstract][Full Text] [Related]
18. Different survival determinants of metastatic breast cancer patients treated with endocrine therapy or chemo-endocrine therapy. Nomura Y Int J Oncol; 1998 Apr; 12(4):817-24. PubMed ID: 9499441 [TBL] [Abstract][Full Text] [Related]
19. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477 [TBL] [Abstract][Full Text] [Related]
20. [Present status of endocrine therapy of breast cancer: a surgeon's view]. Nomura Y Gan To Kagaku Ryoho; 1984 May; 11(5):981-8. PubMed ID: 6426405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]